{
    "clinical_study": {
        "@rank": "16661", 
        "acronym": "CIDAN12", 
        "arm_group": {
            "arm_group_label": "Cidofovir 1%", 
            "arm_group_type": "Experimental", 
            "description": "Cidofovir 1% cream's basis, 2gr, three times per week, during 4 weeks."
        }, 
        "brief_summary": {
            "textblock": "Cidofovir could be an effective drug for the treatment of Anal Intraepithelial\n      Neoplasia(AIN)."
        }, 
        "brief_title": "A Prospective, With One Site, Open-label Not Controled Trial, for the Observation of Treatment With CIDOFOVIR 1%, 3 Nights Per Week, During 4 Weeks, of Anal Intraepithelial Neoplasia, High Level, in HIV+ Patients", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "HIV", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Carcinoma in Situ"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "-  Inclusion Criteria:\n\n               1. Patients who have given informed consent in writing of the study before making\n                  any specific selection procedure for the study.\n\n               2. Adult patients (18 years) with documented HIV infection, with high-grade AIN\n                  demonstrated by biopsy, and have not received any prior treatment for Anal\n                  Intraepithelial Neoplasia in the last 12 weeks.\n\n               3. For women of childbearing potential, negative pregnancy test in urine screening\n                  visit. All women of childbearing age should continue effective contraception\n                  throughout the study treatment.\n\n          -  Exclusion Criteria:\n\n             1. Patients who have received previous treatment of Anal Intraepithelial Neoplasia\n             (AIN) in the last 12 weeks. 2. Dermatoses in patients with anogenital area 3.\n             Patients with a history of pre-invasive neoplasia associated with Human Papilloma\n             Virus 4. Patients with a history of previous neoplasm, of any origin and location, in\n             the past 5 years.\n\n             5. Patients with a history of hematologic abnormalities, kidney or liver 6. Pregnant\n             or breastfeeding women or women of childbearing age who do not wish to use adequate\n             contraception at the discretion of the investigator.\n\n             7. Any disease or condition of the patient which, in the opinion of the investigator,\n             is not adequate patient participation in the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01946009", 
            "org_study_id": "GESIDA-7412"
        }, 
        "intervention": {
            "arm_group_label": "Cidofovir 1%", 
            "intervention_name": "Cidofovir 1% cream's basis, 2gr, three times per week, during 4 weeks.", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Cidofovir"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 29, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Madrid", 
                    "country": "Spain"
                }, 
                "name": "Hospital Universitario La Paz"
            }
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Prospective, With One Site, Open-label Not Controled Trial, for the Observation of Treatment With CIDOFOVIR 1%, 3 Nights Per Week, During 4 Weeks, of Anal Intraepithelial Neoplasia, High Level, in HIV+ Patients", 
        "overall_official": {
            "affiliation": "Hospital La Paz", 
            "last_name": "Elena Sendagorta, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Describe the percentage of patients achieving complete regression of anal intraepithelial neoplasia (AIN), as confirmed by means of high-resolution anoscopy and biopsy", 
            "measure": "Percentage of patients with complete regression of anal intraepithelial neoplasia", 
            "safety_issue": "No", 
            "time_frame": "8 Weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01946009"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Describe the percentage of patients that reduce the degree of Anal dysplasia", 
                "measure": "Describe the percentage of patients that reduce the degree of Anal dysplasia", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "Describe the percentage of patients that reduces the extent Intraepithelial Anal Dysplasia quadrants, although not complete regression", 
                "measure": "Describe the percentage of patients that reduces the extent Intraepithelial Anal Dysplasia quadrants, although not complete regression", 
                "safety_issue": "No", 
                "time_frame": "8 Weeks"
            }, 
            {
                "description": "Describe the percentage of patients with recurrence after complete regression of HSIL and median time to relapse", 
                "measure": "Time to relapse", 
                "safety_issue": "No", 
                "time_frame": "8 Weeks"
            }, 
            {
                "description": "Describe the percentage of patients in whom Human Papillomavirus clears after treatment with cidofovir", 
                "measure": "Percentage of patients with clear of Human papillomavirus", 
                "safety_issue": "No", 
                "time_frame": "8 Weeks"
            }, 
            {
                "description": "Describe the number of patients with adverse events as a measure of safety and tolerability", 
                "measure": "Percentage of adverse events", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "Prospective Clinical Trial exploratory nature of the effect of treatment.", 
                "measure": "Treatment effect", 
                "safety_issue": "No", 
                "time_frame": "8 Weeks"
            }
        ], 
        "source": "Fundacion SEIMC-GESIDA", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fundacion SEIMC-GESIDA", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}